ONCOLOGY

OxStem Oncology is developing a universal differentiation therapy targeting haematological malignancies with a focus on Acute Myeloid Leukaemia (AML). The new medicine is expected to normalise haematopoiesis by differentiating leukemic myeloblasts resulting in complete durable remission for AML patients irrespective of their mutation status.

Read more